Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 8 of 58, showing 10 Applications out of 576 total, starting on record 71, ending on 80

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

71.

ECCT/25/02/02   HPV vaccine feasibility study
    Generating local data on HPV vaccination impact and training needs at the level of vaccine implementers – A feasibility study   
Principal Investigator(s)
1. Prof Kenneth Ngure
Site(s) in Kenya
KEMRI-CCR PHRD( (THIKA) PROJECT
 
29-04-2025 View

72.

ECCT/25/01/03   FETAL LITE STUDY
    Evaluation of Fetal Lite Device for Reducing Perinatal Mortality through Enhanced Labor Monitoring in Low-Resource Settings: A Pilot Study at Kenyatta National Hospital   
Principal Investigator(s)
1. GEORGE GWAKO
2. Alfred Osoti
3. Rosa Chemwey
Site(s) in Kenya
Kenyatta National Hospital
 
13-05-2025 View

73.

ECCT/25/02/10   PrEP My Way II
    PrEP My Way: A hybrid type 1 clinical effectiveness-implementation trial to promote PrEP persistence among young Kenyan women   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI RCTP
 
17-06-2025 View

74.

ECCT/24/12/03   PrEMIA Implementation study
    Multi-product PrEP delivery to young women seeking reproductive health services and coverage of HIV prevention   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD( (THIKA) PROJECT
 
04-05-2025 View

75.

ECCT/25/01/01   FLORAL
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Bernhard Ogutu
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
2. Gertrude’s Children’s Hospital (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
 
24-04-2025 View

76.

ECCT/24/12/01   PDMC-Saves Lives (PDMC-SL)
    Delivery strategies for malaria chemoprevention in the post-discharge management of hospitalised children with severe anaemia or severe malaria: cluster and individually randomised controlled implementation trials with nested economic evaluation in Kenya and Benin   
Principal Investigator(s)
1. Juliet Otieno Awori
2. Simon Kariuki
Site(s) in Kenya
Health facilities with blood transfusion services in malaria-endemic areas in Western Kenya
 
16-04-2025 View

77.

ECCT/24/12/02   IAVI C113
    IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region.   
Principal Investigator(s)
1. Videlis Nduba
2. Tina Lucas
Site(s) in Kenya
1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
 
21-05-2025 View

78.

ECCT/25/03/01   MK-5684_MSD (mCRPC)
     A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)    
Principal Investigator(s)
1. PROF MANSOOR NOORALI SALEH
Site(s) in Kenya
AGA KHAN UNIVERSITY HOSPITAL NAIROBI
 
20-05-2025 View

79.

ECCT/24/11/03   REALISE STUDY PROTOCOL
    A Pragmatic Phase III Multi-Centre Clinical Trial to Evaluate the Safety and 1 Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs 2 Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in 3 School-Aged Children   
Principal Investigator(s)
1. Alejandro Javier Krolewiecki
Site(s) in Kenya
Kwale county
 
19-06-2025 View

80.

ECCT/24/11/01   Sparkle
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Site 1401:Victoria Biomedical Research Institute (Kisumu county)
2. Site 1402:Ahero Clinical trials Unit (Kisumu county)
3. Site 1403:International Cancer institute (Uasin Gishu county)
4. Site 1404:Kondele Childrens Hospital (Kisumu county)
5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county)
6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county)
 
13-05-2025 View